biotech licensing
Aditum forms new company for China-sourced asset in $1B deal
Aditum; China-sourced asset; $1B deal; newco; Mabwell; dyslipidemia; vascular disorders; biotech licensing; cross-border pharma
Actionable Insights Powered by AI
Aditum; China-sourced asset; $1B deal; newco; Mabwell; dyslipidemia; vascular disorders; biotech licensing; cross-border pharma